Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Front Immunol ; 13: 1034379, 2022.
Article in English | MEDLINE | ID: mdl-36275757

ABSTRACT

Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen-HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 - paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and ex-vivo inflammatory bioactivity on endothelial cells. We didn't observe significant modulation of the majority of inflammatory soluble factors (8 of 10 molecules tested) pre- or post-PRT. We noted that IL-8 concentrations were significantly decreased in cFFP with PRT, whereas the IL-18 concentration was increased by PRT. In contrast, endothelial cell release of IL-6 was similar whether cFFP was pre-treated with or without PRT. Expression of CD54 and CD31 in the presence of cFFP were similar to control levels, and both were significant decreased in when cFFP had been pre-treated by PRT. It will be interesting to continue investigations of IL-18 and IL-8, and the physiopathological effect of PRT- treated convalescent plasma and in clinical trials. But overall, it appears that cFFP post-PRT were not excessively pro-inflammatory. Further research, including a careful clinical evaluation of CCP-treated patients, will be required to thoroughly define the clinical relevance of these findings.


Subject(s)
COVID-19 , Pandemics , Humans , COVID-19/therapy , Endothelial Cells , Interleukin-10 , Interleukin-18 , Interleukin-1beta , Interleukin-6 , Interleukin-8 , Technology , Tumor Necrosis Factor-alpha , Ultraviolet Rays , COVID-19 Serotherapy
2.
Presse Med ; 44(2): 214-20, 2015 Feb.
Article in French | MEDLINE | ID: mdl-25578550

ABSTRACT

The level of safety attained in blood transfusion now makes this a discipline better managed care activities. This was achieved both by scientific advances and policy decisions regulating and supervising the activity, as well as by the quality system, which we recall that affects the entire organizational structure, responsibilities, procedures, processes and resources in place to achieve quality management. So, an effective quality system provides a framework within which activities are established, performed in a quality-focused way and continuously monitored to improve outcomes. This system quality has to irrigate all the actors of the transfusion, just as much the establishments of blood transfusion than the health establishments.


Subject(s)
Blood Banks/organization & administration , Blood Safety , Blood Specimen Collection , Safety Management/methods , Safety Management/organization & administration , Transfusion Reaction , Blood Donors/supply & distribution , Blood Safety/methods , Blood Safety/standards , Blood Specimen Collection/adverse effects , Blood Specimen Collection/methods , Blood Specimen Collection/standards , Blood Transfusion/methods , Blood Transfusion/standards , Donor Selection/methods , Donor Selection/organization & administration , Humans , Quality Assurance, Health Care
SELECTION OF CITATIONS
SEARCH DETAIL
...